

# Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

## MIA PaCa-2

RRID:CVCL\_0428

Type: Cell Line

### Proper Citation

RRID:CVCL\_0428

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0428](https://web.expasy.org/cellosaurus/CVCL_0428)

**Proper Citation:** RRID:CVCL\_0428

**Description:** Cell line MIA PaCa-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Pancreatic undifferentiated carcinoma

**Defining Citation:** [PMID:832918](#), [PMID:1630814](#), [PMID:1764370](#), [PMID:7809022](#), [PMID:7961102](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:9290701](#), [PMID:10027410](#), [PMID:11115575](#), [PMID:11169957](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:12068308](#), [PMID:12692724](#), [PMID:14695172](#), [PMID:15770730](#), [PMID:16912165](#), [PMID:17254797](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:18575732](#), [PMID:19077451](#), [PMID:19188929](#), [PMID:19904223](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23386380](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25485960](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26884312](#), [PMID:27067801](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31037374](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32782605](#), [PMID:34207840](#), [PMID:35839778](#)

**Comments:** Caution: Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MIA PaCa-2

**Synonyms:** MIA-PaCa-2, MIA-PACA-2, MIA-Pa-Ca-2, MIA Paca2, MIA PaCa2, MiaPaCa-2, MIAPACA-2, MiaPaca.2, MiaPaCa2, Miapaca2, MIAPaCa2, MIAPACA2, Mia PACA 2, MIAPaCa-2, PaCa2, MiaPaCa, MIAMI Pancreatic Carcinoma-2

**Cross References:** BTO:BTO\_0002137, CLO:CLO\_0007726, CLO:CLO\_0050101, EFO:EFO\_0002236, MCCL:MCC:0000325, CLDB:cl3480, CLDB:cl3481, CLDB:cl3482, AddexBio:C0018002/59, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3263, ArrayExpress:E-MTAB-3610, ATCC:CRL-1420, ATCC:CRM-CRL-1420, BCRC:60139, BCRJ:0174, BioGRID\_ORCS\_Cell\_line:544, BioSample:SAMN01821579, BioSample:SAMN01821700, BioSample:SAMN03472131, BioSample:SAMN10988205, cancercellines:CVCL\_0428, CCRID:3101HUMSCSP568, CCRID:4201HUM-CCTCC00255, CCTCC:GDC0255, Cell\_Model\_Passport:SIDM00505, CGH-DB:321-1, CGH-DB:9374-4, ChEMBL-Cells:ChEMBL3308500, ChEMBL-Targets:ChEMBL614725, CLS:300438, Cosmic:707249, Cosmic:710861, Cosmic:719677, Cosmic:724644, Cosmic:724870, Cosmic:730532, Cosmic:808172, Cosmic:868243, Cosmic:872996, Cosmic:913313, Cosmic:918056, Cosmic:922249, Cosmic:923170, Cosmic:932520, Cosmic:947399, Cosmic:948373, Cosmic:948731, Cosmic:949234, Cosmic:968107, Cosmic:1006368, Cosmic:1066202, Cosmic:1108337, Cosmic:1198208, Cosmic:1299302, Cosmic:1320461, Cosmic:1366278, Cosmic:1477431, Cosmic:1534318, Cosmic:1571779, Cosmic:1609545, Cosmic:1644314, Cosmic:1995507, Cosmic:2434084, Cosmic:2664042, Cosmic:2668287, Cosmic:2755950, Cosmic-CLP:724870, DepMap:ACH-000601, DSMZ:ACC-733, DSMZCellDive:ACC-733, ECACC:85062806, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5\_SSTAR:10488-107B2, FCS-free:216-2-440-1-3-6, GDSC:724870, GEO:GSM206526, GEO:GSM244425, GEO:GSM621895, GEO:GSM784703, GEO:GSM887320, GEO:GSM888396, GEO:GSM1024404, GEO:GSM1374677, GEO:GSM1374678, GEO:GSM1374679, GEO:GSM1435696, GEO:GSM1435697, GEO:GSM1435698, GEO:GSM1588612, GEO:GSM1588624, GEO:GSM1670109, GEO:GSM5481591, GEO:GSM5481592, GEO:GSM5481593, GEO:GSM5481594, IARC\_TP53:316, IGRhCellID:MIAPaCa, IZSLER:BS TCL 42, JCRB:JCRB0070, KCLB:21420, LiGeA:CCL\_231, LINCS\_LDP:LCL-1738, Lonza:751, MetaboLights:MTBLS812, NCBI\_Iran:C459, PharmacDB:MIAPaCa2\_931\_2019, PRIDE:PXD001260, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL\_0428, PubChem\_Cell\_line:CVCL\_0428, RCB:RCB2094, SKY/M-FISH/CGH:1996, TKG:TKG 0227, Wikidata:Q54905679

**ID:** CVCL\_0428

**Record Creation Time:** 20220427T220808+0000

**Record Last Update:** 20260905T181145+0000

---

## Ratings and Alerts

No rating or validation information has been found for MIA PaCa-2.

No alerts have been found for MIA PaCa-2.

---

## Data and Source Information

## Usage and Citation Metrics

We found 1066 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Treekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. *Nature cell biology*, 28(1), 197.

Sekiguchi N, et al. (2026)

Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

. *International journal of oncology*, 68(3).

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, 84, 101312.

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. *Cell metabolism*, 38(1), 174.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Garczyk M, et al. (2026) Targeting PI3K $\gamma$  suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. *Cell reports*, 45(4), 117188.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Drouillard D, et al. (2026) Mutant KRAS promotes NF- $\kappa$ B driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for biology*.

Jungwirth J, et al. (2026) The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e23697.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8<sup>+</sup> T cell infiltration in pancreatic ductal adenocarcinoma. *iScience*, 29(7), 116500.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and  $\alpha$ 3 $\beta$ 1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.

Kaur T, et al. (2026) Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. *Molecular cancer research : MCR*, 24(1), 34.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Hosogane M, et al. (2026) Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. *iScience*, 29(1), 114303.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(14), e14735.

Frädrich J, et al. (2026) Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. *Cell reports. Medicine*, 7(1), 102546.

Álvaro BS, et al. (2026) Synthesis of Benzopyrans and Quinolines with Nitrogenated Chain and Their Cytotoxicity Against Human Cancer Cell Lines. *ChemMedChem*, 21(2), e202500904.

Liang X, et al. (2026) CK2-mediated HDAC5 shuttling regulates DNA end resection through Ku70 deacetylation. *Theranostics*, 16(7), 3648.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Dai H, et al. (2026) 5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer. *ACS omega*, 11(7), 12461.